ES2531547T3 - Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores - Google Patents

Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores Download PDF

Info

Publication number
ES2531547T3
ES2531547T3 ES10012266.2T ES10012266T ES2531547T3 ES 2531547 T3 ES2531547 T3 ES 2531547T3 ES 10012266 T ES10012266 T ES 10012266T ES 2531547 T3 ES2531547 T3 ES 2531547T3
Authority
ES
Spain
Prior art keywords
cells
taurolidine
compound
mammal
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10012266.2T
Other languages
English (en)
Spanish (es)
Inventor
Paul Calabresi
James Darnowski
James Costin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2531547(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Application granted granted Critical
Publication of ES2531547T3 publication Critical patent/ES2531547T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES10012266.2T 1999-12-06 2000-12-06 Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores Expired - Lifetime ES2531547T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16912799P 1999-12-06 1999-12-06
US16912899P 1999-12-06 1999-12-06
US16912299P 1999-12-06 1999-12-06
US169127P 1999-12-06
US169122P 1999-12-06
US169128P 1999-12-06

Publications (1)

Publication Number Publication Date
ES2531547T3 true ES2531547T3 (es) 2015-03-17

Family

ID=27389609

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10012266.2T Expired - Lifetime ES2531547T3 (es) 1999-12-06 2000-12-06 Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores
ES06019082.4T Expired - Lifetime ES2438535T3 (es) 1999-12-06 2000-12-06 Taurolidina o taurultamo para uso en el tratamiento de tumores de próstata, de colon, de pulmón y para el tratamiento del glioblastoma multiforme recurrente

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06019082.4T Expired - Lifetime ES2438535T3 (es) 1999-12-06 2000-12-06 Taurolidina o taurultamo para uso en el tratamiento de tumores de próstata, de colon, de pulmón y para el tratamiento del glioblastoma multiforme recurrente

Country Status (9)

Country Link
US (6) US6521616B2 (enExample)
EP (3) EP1248625A2 (enExample)
JP (5) JP5027369B2 (enExample)
AT (1) ATE339207T1 (enExample)
AU (2) AU784539B2 (enExample)
CA (3) CA2393252A1 (enExample)
DE (1) DE60030770T2 (enExample)
ES (2) ES2531547T3 (enExample)
WO (2) WO2001039763A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20020098164A1 (en) 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
EP1797884B1 (en) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
WO2002074294A1 (en) * 2001-03-15 2002-09-26 Rhode Island Hospital, A Lifespan Partner Taurine compounds
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US6753328B2 (en) 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
DE60306828T2 (de) * 2002-03-21 2007-08-02 Ed. Geistlich Söhne AG für chemische Industrie, Wolhusen Vorrichtung für Behandlung eines Tumors im zentralen Nervensystem
ES2285251T3 (es) * 2002-09-24 2007-11-16 Novartis Ag Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
AU2004201264B2 (en) * 2003-03-28 2009-12-24 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Adhesive Antineoplastic Compositions
US20050008684A1 (en) * 2003-07-10 2005-01-13 Claus Herdeis Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition
US8236794B2 (en) * 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
WO2006009765A2 (en) * 2004-06-18 2006-01-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
HRP20181379T1 (hr) * 2005-07-19 2018-11-16 Stemgen S.P.A. Inhibiranje tumorogenog potencijala tumorskih matičnih stanica s bmp-4
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
CA2636217C (en) 2006-01-06 2014-02-25 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
WO2008030413A1 (en) * 2006-09-05 2008-03-13 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of improving renal function
CN101528195B (zh) * 2006-09-07 2012-03-28 埃德盖斯特利希索恩化学工业股份公司 羟甲基转移剂在制备治疗骨癌的药物中的用途
EP2240175B1 (en) * 2008-02-11 2013-01-02 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Compounds with mdr1-inverse activity
DE102010010360A1 (de) * 2010-03-05 2011-09-08 Gamptec Gmbh Formulierungen von Taurolidin und Verfahren zu seiner Herstellung
ES2614878T3 (es) * 2010-06-01 2017-06-02 Geistlich Pharma Ag Métodos y composiciones para terapia farmacéutica oral
EP2621458B1 (en) 2010-09-27 2017-04-19 Geistlich Pharma AG Antimicrobial dental care preparation
PL2861573T3 (pl) 2012-06-18 2018-02-28 Geistlich Pharma Ag Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe
CA2930359C (en) * 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EP3377067A4 (en) * 2015-10-07 2019-07-31 Cormedix Inc. SKIN-PENETRATING FORMULATION OF TAUROLIDINE
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
JP7614714B2 (ja) * 2016-01-11 2025-01-16 コーメディクス・インコーポレーテッド 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
WO2018126133A1 (en) * 2016-12-29 2018-07-05 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN109929804B (zh) * 2017-12-15 2020-10-16 天津医科大学肿瘤医院 一种人卵巢癌细胞系及其制备方法和应用
CN113347976A (zh) * 2018-08-28 2021-09-03 科医公司 用牛磺罗定水解产物进行的神经母细胞瘤治疗
CN113164491A (zh) * 2018-08-28 2021-07-23 科医公司 用于治疗幼年哺乳动物体内神经母细胞瘤的方法和组合物
AU2019331913B2 (en) * 2018-08-31 2025-06-26 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
WO2020234829A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
GB1408010A (en) 1972-11-20 1975-10-01 Geistlich Soehne Ag Sulphamoylphenyl-imidazolidinones
GB1557163A (en) 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
US4107305A (en) 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
GB1588110A (en) * 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
JPS5598170A (en) * 1979-01-18 1980-07-25 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
US4337251A (en) 1979-05-09 1982-06-29 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of avoiding and removing adhesions
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328074D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
GB8328073D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5573771A (en) 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
GB8827986D0 (en) 1988-11-30 1989-01-05 Geistlich Soehne Ag Chemical product
US5819748A (en) 1988-11-30 1998-10-13 Ed Geistlich Sohne Ag Fur Chemische Industrie Implant for use in bone surgery
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
GB9005856D0 (en) 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
DE69104608T2 (de) * 1991-07-04 1995-02-16 Weissenfluh Hawe Neos Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
GB9216155D0 (en) * 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5954687A (en) * 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
DE19606897C2 (de) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren
AU734460B2 (en) * 1997-05-22 2001-06-14 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6011030A (en) * 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose

Also Published As

Publication number Publication date
CA2393252A1 (en) 2001-06-07
US20020052366A1 (en) 2002-05-02
US20030100551A1 (en) 2003-05-29
US6521616B2 (en) 2003-02-18
CA2696185A1 (en) 2001-06-07
EP2332542A3 (en) 2011-09-28
JP2012136540A (ja) 2012-07-19
DE60030770D1 (de) 2006-10-26
AU784539B2 (en) 2006-04-27
US6995164B2 (en) 2006-02-07
AU2065001A (en) 2001-06-12
AU2064901A (en) 2001-06-12
CA2393159C (en) 2010-04-20
US20020049200A1 (en) 2002-04-25
JP5027369B2 (ja) 2012-09-19
JP5829948B2 (ja) 2015-12-09
EP1246617A2 (en) 2002-10-09
EP1246617B1 (en) 2006-09-13
US6703413B2 (en) 2004-03-09
CA2393159A1 (en) 2001-06-07
US20030078257A1 (en) 2003-04-24
JP2014198739A (ja) 2014-10-23
JP2003515558A (ja) 2003-05-07
US20020111345A1 (en) 2002-08-15
EP2332542A2 (en) 2011-06-15
JP2016188244A (ja) 2016-11-04
DE60030770T2 (de) 2007-09-06
CA2696185C (en) 2014-09-23
ES2438535T3 (es) 2014-01-17
WO2001039763A3 (en) 2002-07-11
JP6234340B2 (ja) 2017-11-22
JP2003515557A (ja) 2003-05-07
ATE339207T1 (de) 2006-10-15
WO2001039762A3 (en) 2002-05-02
AU784538B2 (en) 2006-04-27
EP1248625A2 (en) 2002-10-16
US6964959B2 (en) 2005-11-15
WO2001039763A2 (en) 2001-06-07
EP2332542B1 (en) 2015-02-11
US6429224B1 (en) 2002-08-06
WO2001039762A2 (en) 2001-06-07
US20060135513A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ES2531547T3 (es) Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores
ES2316188T3 (es) Tratamiento de transtornos hiperproliferativos.
DeVita Jr et al. Combination chemotherapy in the treatment of advanced Hodgkin's disease
Carchman et al. The inhibition of DNA synthesis by cannabinoids
Carter et al. Plant products in cancer chemotherapy
Von Hoff et al. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule
UA125892C2 (uk) Інгібітор кінази aurora а для застосування в лікуванні нейробластоми
TW201615200A (zh) 偏亞砷酸鈉於治療白血病及淋巴瘤之用途
Bellett et al. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma
AU756762B2 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
EP1526851B1 (en) Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
Allen et al. Hepatic toxicity of tetracycline in pregnancy
Young et al. Treatment of malignant melanoma with methyl CCNU
Bonder et al. Use of mouse vaginal and rectal epithelium to screen antimitotic effects of systemically administered drugs
AU2004296863B2 (en) Synergistic anti-cancer compositions
Gold et al. A comparative study with three alkylating agents: mechlorethamine, cyclophosphamide, and uracil mustard
Pizzocaro et al. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results
ES2978336T3 (es) Combinación de un inhibidor de Mcl-1 y midostaurina, usos y composiciones farmacéuticas de la misma
Wittes et al. Chemotherapy of head and neck cancer: Combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin
Tamura et al. Effect of anticancer agents on cell cycle of regenerating hepatocytes in rats
CA2441016A1 (en) Taurine compounds
Cardoso et al. Circadian mitotic rhythm as a guide for the administration of antimetabolites
Marley Non-thrombocytopenic Purpura after Chlorpromazine
Hepburn et al. Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line
Taylor et al. Effect of secretogogues on mucosal blood flow in the antrum and corpus of the stomach.